GRPH News and Press, Graphite Bio Inc. From 03/21/22

Patient enrollment in Phase 1/2 CEDAR clinical trial of GPH101 for sickle cell disease ongoing at multiple sites; dosing of first patient now planned for second half of 2022, with initial proof-of-concept data anticipated in 2023 Prioritized R&D to maximize capabilities of...

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced today that Josh Lehrer, M.D., chief executive officer of Graphite Bio, will be a featured sp...

Graphite Bio (NASDAQ:GRPH) has appointed Alethia Young as Chief Financial Officer (CFO), effective Apr. 1, 2022. In this newly created position, Ms. Young will oversee the gene editing company's finance, investor relations and corporate communications functions. Prior to this appointment, You...

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the appointment of Alethia Young as chief financial officer. Ms. Young joins Graphite ...

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced participation in the following upcoming investor conferences: Cowen 2 nd A...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...

Trial-in-progress poster presentation provides overview of first-in-human Phase 1/2 clinical trial in participants with severe sickle cell disease designed to evaluate safety, efficacy and pharmacodynamics of GPH101 Initial proof-of-concept data from CEDAR trial anticipated by...

Virtual event on Tuesday, December 14, 2021, at 3 p.m. ET to discuss how the company’s differentiated gene correction approach using GPH101 could lead to curative outcomes Webinar to include an encore of the company’s poster presentation of the Phase 1/2 CEDAR Tr...

Shares of Graphite Bio (GRPH +9.0%) are up in afternoon trading after venture capital firm Samsara BioCapital disclosed it added to its position in the company. Samsara bought 201,685 shares at an average of $10.15. The firm now has a total of ~7.8M shares. Seeking Alpha contributor Terry Chr...

Graphite Bio Initiated the phase 1/2 CEDAR trial using GPH101 for a potential curative treatment of patients with severe sickle-cell disease. First patient in phase 1/2 CEDAR trial will be dosed in the 1st half of 2022 and the first set of results are expected in the 2nd half of 2022....